Austria said there is currently "no evidence of a causal relationship" after one woman died and another developed a pulmonary embolism after receiving doses from the same batch of the COVID-19 vaccine from Oxford-AstraZeneca, BBC News reported on Monday.
The country's Federal Office for Safety in Health Care stated on 7 March 2021 that an investigation was "running at full speed in order to be able to completely exclude a possible connection," adding that the remaining doses from the batch will not be used as a precaution.
However, the Federal Office noted that blood clotting issues "are not among the known or typical side effects of the vaccine in question" and that no similar cases had been linked to the Oxford-AstraZeneca vaccine.
The EU had approved the Oxford-AstrazEneca COVID-19 vaccine in late January 2021.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne